ICD-10 Code D69.3: Immune thrombocytopenic purpura

Key Takeaways

ICD-10 Code D69.3 (Immune Thrombocytopenic Purpura) is a billable ICD-10-CM diagnosis code valid for reimbursement from October 1, 2015 onwards.

Use D69.3 for primary ITP only when secondary thrombocytopenia causes have been clinically excluded; secondary cases require D69.5x codes instead.

Inclusion terms include Hemorrhagic (thrombocytopenic) purpura, Idiopathic thrombocytopenic purpura, and Tidal platelet dysgenesis.

Pabau’s claims management software and digital forms streamline ITP documentation workflows, reducing coding errors and supporting clean claim submission.

Most coding denials for thrombocytopenia-related diagnoses trace back to a single mistake: applying D69.3 without ruling out secondary causes. When secondary thrombocytopenia goes undetected in the documentation, the wrong code ships on the claim, and the payer pushes back. Specifically, the ICD-10 Code D69.3 (Immune Thrombocytopenic Purpura) applies only to primary, immune-mediated platelet destruction confirmed through clinical exclusion, and the documentation burden that comes with it is significant. This reference covers the official code definition, inclusion terms, diagnostic criteria, related codes, and the documentation requirements coders and clinicians need to bill D69.3 accurately.

ICD-10-CM updates annually. This reference reflects the 2026 code set, maintained jointly by the Centers for Medicare and Medicaid Services (CMS) and the National Center for Health Statistics (NCHS). Reimbursement claims with a date of service on or after October 1, 2015 require ICD-10-CM codes.

ICD-10 Code D69.3: Immune thrombocytopenic purpura – definition and classification

ICD-10 Code D69.3 (Immune Thrombocytopenic Purpura) designates thrombocytopenia occurring in the absence of toxic exposure or a disease otherwise associated with decreased platelet counts. The mechanism is immune-mediated: IgG autoantibodies attach to platelet surface antigens, marking them for destruction by macrophages in the spleen and liver. As a result, the platelet count drops low enough to cause spontaneous bleeding, purpuric skin lesions, and bruising.

D69.3 sits within the following ICD-10-CM hierarchy, which coders can verify using the CDC/NCHS ICD-10-CM web tool:

The code is billable and specific. It requires no additional digit for further specificity, making it appropriate for final diagnosis submission. Review related hemorrhagic condition coding when documenting comorbid bleeding disorders alongside ITP.

Inclusion terms and synonyms for D69.3

Three inclusion terms appear in the official ICD-10-CM tabular list under D69.3. When any of these terms appears in the clinical documentation, D69.3 is the correct code assignment.

• Hemorrhagic (thrombocytopenic) purpura – purpuric bleeding attributable to immune-mediated platelet destruction
• Idiopathic thrombocytopenic purpura – the historical term still used in many clinical notes; maps directly to D69.3
• Tidal platelet dysgenesis – a rare cyclic variant of ITP with periodic platelet fluctuations

Coders often encounter “ITP” as an abbreviation in clinical notes. Before assigning D69.3, confirm the full term against medical history and lab findings. When the record is ambiguous, query the treating physician. Proper clinical documentation at your healthcare practice reduces ambiguity at the coding stage.

When to use ICD-10 Code D69.3: diagnostic criteria

D69.3 applies when the clinical record supports primary, immune-mediated thrombocytopenia with secondary causes excluded. Platelet counts below 100,000/µL serve as a widely accepted clinical threshold, though the precise cutoff may vary by institution and treating clinician. The diagnosis of exclusion is what separates D69.3 from the D69.5x family of secondary thrombocytopenia codes.

Documentation should support all four of the following criteria before D69.3 is assigned:

• Low platelet count confirmed by CBC, typically below 100,000/µL
• Purpuric lesions observed on extremities or mucous membranes, or documented bleeding symptoms (nosebleeds, prolonged wound bleeding, excessive menstrual bleeding)
• Exclusion of secondary causes: medication-induced thrombocytopenia, infections (HIV, hepatitis C), hematological malignancies, and autoimmune conditions evaluated and ruled out
• Immune mechanism confirmed: antiplatelet antibody testing, bone marrow examination findings, or clinical presentation consistent with IgG-mediated platelet destruction

In addition, ITP is classified by phase, which affects clinical management but does not change the ICD-10-CM code assignment: acute (under 3 months), persistent (3 to 12 months), and chronic (over 12 months). Coders should note the phase in documentation for audit trail purposes even though D69.3 does not differentiate between phases. Accurate patient record documentation capturing phase and lab findings strengthens medical necessity support.

D69.3 vs secondary thrombocytopenia: choosing the correct code

Misapplying D69.3 when thrombocytopenia is secondary to another condition is one of the most common ITP coding errors. The distinction is clinical, not administrative: primary ITP has no identifiable cause, while secondary thrombocytopenia is attributable to an underlying disease, medication, or external trigger.

For more context on how ICD-10-CM differentiates similar diagnostic codes, the AAPC Codify ICD-10-CM lookup provides detailed code notes and excludes1/excludes2 annotations. Coding teams managing complex hematology claims benefit from referencing the ICD-10 diagnostic coding methodology used across similar primary vs. secondary distinctions.

Documentation requirements for ICD-10 Code D69.3 immune thrombocytopenic purpura

Payer scrutiny of ITP claims has increased because D69.3 frequently appears alongside high-cost procedures such as IVIG infusions (CPT 96365-96368) and splenectomy. Incomplete documentation drives the majority of claim denials and post-payment audit recoupments for ITP encounters.

A compliant D69.3 encounter note should capture:

• Confirmed platelet count from current CBC with the date of the lab draw
• Clinical presentation: type and location of bleeding or purpuric lesions, patient-reported symptoms
• Exclusion workup: medications reviewed, infection screening results (HIV, hepatitis B and C), bone marrow or antiplatelet antibody findings if performed
• ITP phase: acute, persistent, or chronic, with onset date or duration noted
• Treatment plan: corticosteroids, IVIG, thrombopoietin receptor agonists, or splenectomy indication documented with clinical rationale
• Provider attestation: the diagnosing physician must sign and date the note for billing purposes under HIPAA-compliant record standards

HIPAA-compliant documentation practices govern how this clinical information is stored and transmitted. Practices using digital intake and clinical forms reduce the risk of missing fields at point of care. Furthermore, combining structured form capture with AI-assisted clinical documentation further reduces transcription gaps in ITP notes. For broader context on keeping records secure and audit-ready, review HIPAA compliance for clinic software.

Coding guidelines and billing context for D69.3

WHO’s ICD-10 classification covers D69.3, and CMS adopted it for US billing through the ICD-10-CM system. CMS mandated the ICD-10-CM transition effective October 1, 2015. Claims with dates of service before that date use ICD-9-CM; claims from October 1, 2015 onwards require ICD-10-CM.

Key billing guidance for encounters coded with D69.3:

• Sequencing: when ITP is the reason for the encounter, list D69.3 as the principal diagnosis. If ITP is a comorbidity being managed during an encounter for another condition, sequence accordingly by reason for visit.
• IVIG infusion coding: For example, IVIG therapy for ITP requires both the infusion CPT code and D69.3 as the supporting diagnosis. Payers commonly require prior authorization; document medical necessity explicitly.
• Splenectomy: when documenting a splenectomy for refractory ITP, D69.3 serves as the indication code. The operative report must confirm the ITP diagnosis and treatment rationale.
• Pediatric vs. adult ITP: D69.3 applies to both age groups. Pediatric ITP often resolves spontaneously within 6 months; document age and clinical course to support appropriate management coding.
• Modifier use: no standard modifiers are specific to D69.3 alone, but modifiers on associated procedure codes (e.g., infusion codes) follow standard CMS guidelines.

Practices with high hematology or infusion billing volumes benefit from claims management systems that flag documentation gaps before submission. Pabau’s claims management software supports clean claim workflows across complex diagnosis-procedure pairings. Practices managing ITP alongside other blood disorder diagnoses can also find coding context in related ICD-10 diagnostic code references to understand how multi-code encounters are sequenced. The ICD List provides a free lookup for DRG groupers and code edits relevant to D69.3 claims.

Reduce ITP coding errors with Pabau

Pabau's claims management and digital documentation tools help hematology and specialty practices capture the clinical evidence D69.3 requires, before the claim leaves the practice.

Book a demo

Related ICD-10-CM codes for ITP and purpura

D69.3 does not exist in isolation. Coders working with ITP encounters regularly encounter the following adjacent codes. Understanding their boundaries prevents misclassification and reduces audit risk.

By contrast, Evans syndrome (D69.41) is a common source of confusion. When a patient presents with both ITP and autoimmune hemolytic anemia, the correct code is D69.41, not D69.3. The presence of the autoimmune hemolytic component changes the classification entirely. Clinics running complex hematology or oncology billing can integrate this code reference with secure patient data security tools that support structured, auditable records.

Conclusion

Ultimately, getting D69.3 right depends on one thing: documented evidence that the clinician excluded secondary thrombocytopenia. Without that clinical foundation, the code becomes a liability rather than an asset on the claim. Practices that invest in structured documentation workflows, where every CBC result, exclusion test, and treatment rationale is captured at the point of care, submit cleaner claims and face fewer denials.

Pabau’s claims management software and structured digital forms help specialty and hematology practices build that foundation systematically. To see how Pabau handles complex diagnosis documentation from intake to claim submission, book a demo.

Continue your research

Need a structured approach to clinical documentation? Safer clinical notes guide covers how to write audit-ready notes that support accurate coding.

Managing compliance across your practice? Pabau compliance management software supports structured workflows for HIPAA-aligned documentation and record retention.

Looking for ICD-10 context across other diagnostic categories? ICD-10 diagnostic code reference illustrates how primary vs. secondary distinctions apply across specialties.

Frequently Asked Questions